Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 25
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic significance of mutation type and chromosome fragility in Fanconi anemia

  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Persico, Ilaria
  • Cavero, Debora|||0000-0002-8912-1890
  • de la Cal, Aurora
  • Río, Paula
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Casado, José A.|||0000-0003-2479-1508
  • Bailador, Almudena
  • Sanchez de la Fuente, Antonio
  • López de Heredia, Miguel|||0000-0003-2826-9565
  • Almazán Castro, Francisco|||0000-0001-6894-9376
  • Antelo, Maria Luisa|||0000-0002-4280-4432
  • Argilés, Bienvenida
  • Badell Serra, Isabel|||0000-0001-6546-2175
  • Baragaño, Marta|||0000-0002-4041-2021
  • Beléndez, Cristina|||0000-0002-6019-6557
  • Bermúdez, Mar
  • Bernués, Marta
  • Buedo Rubio, María Isabel|||0000-0002-2967-1647
  • Carrasco, Estela|||0000-0003-1964-7675
  • Català, Albert|||0000-0003-0133-1752
  • Costa, Dolors|||0000-0002-8276-3292
  • Cuesta, Isabel
  • Fernandez-Delgado, Rafael
  • Fernandez-Teijeiro, Ana|||0000-0002-2359-9330
  • Figuera, Ángela
  • García, Marta|||0000-0001-5155-4730
  • Gondra, Ainhoa
  • González Cruz, Macarena
  • González Muñiz, Soledad
  • Hernandez-Rodriguez, Inés|||0000-0003-2550-9041
  • Ibañez, Fátima
  • Kelleher, Nicholas John
  • Lendínez, Francisco
  • Lopez Rodriguez, Monica|||0000-0001-8134-9682
  • López-Almaraz, Ricardo
  • Marchante, Inmaculada
  • Mendoza, Carmen
  • Nieto, José
  • Ojeda, Emilio
  • Payán-Pernía, Salvador|||0000-0002-4288-7362
  • Peláez, Irene
  • Pérez de Soto, Inmaculada
  • Portugal, Raquel|||0000-0002-7144-9409
  • Ramos-Arroyo, María A.|||0000-0002-7171-9202
  • Regueiro, Alexandra
  • Rodríguez, Ana
  • Rosell, Jordi
  • Saez, Raquel
  • Sánchez, José
  • Sánchez, Martha
  • Senent, Maria Leonor
  • Tapia, María
  • Trujillo-Quintero, Juan Pablo|||0000-0001-5901-9388
  • Vagace Valero, José Manuel|||0000-0001-8751-4319
  • Verdú-Amorós, Jaime|||0000-0002-0900-0889
  • Verdugo, Victória
  • Vidales, Isabel
  • Villarreal, Jasson
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Sevilla, Julián|||0000-0002-6852-1860
  • Bueren, Juan|||0000-0002-3228-7013
  • Surralles, Jordi|||0000-0002-4041-7519
Fanconi anemia (FA) is a rare genetic disease characterized by high phenotypic and genotypic heterogeneity, and extreme chromosome fragility. To better understand the natural history of FA, identify genetic risk and prognostic factors, and develop novel therapeutic strategies, the Spanish Registry of Patients with FA collects data on clinical features, chromosome fragility, genetic subtypes, and DNA sequencing with informed consent of participating individuals. In this article, we describe the clinical evolution of 227 patients followed up for up to 30 years, for whom our data indicate a cumulative cancer incidence of 86% by age 50. We found that patients with lower chromosome fragility had a milder malformation spectrum and better outcomes in terms of later-onset hematologic impairment, less severe bone marrow failure, and lower cancer risk. We also found that outcomes were better for patients with mutations leading to mutant FANCA protein expression (genetic hypomorphism) than for patients lacking this protein. Likewise, prognosis was consistently better for patients with biallelic mutations in FANCD2 (mainly hypomorphic mutations) than for patients with biallelic mutations in FANCA and FANCG, with the lack of the mutant protein in patients with biallelic mutations in FANCG contributing to their poorer outcomes. Our results regarding the clinical impact of chromosome fragility and genetic hypomorphism suggest that mutant FA proteins retain residual activity. This finding should encourage the development of novel therapeutic strategies aimed at partially or fully enhancing mutant FA function, thereby preventing or delaying bone marrow failure and cancer in patients with FA. Clinical Trial Registration number: NCT06490510.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Paleogene kinematics of the central Catalan Coastal Ranges, temporal constraints from magneto-chronology and provenance analysis in synorogenic deposits in the SE margin of the Ebro Basin (NE Spain)

  • Marín, Miquel
  • Carola Molas, Eloi|||0000-0003-2528-150X
  • Beamud, Elisabet|||0000-0003-3158-2966
  • Bover-Arnal, Telm|||0000-0002-5599-3711
  • López-Blanco, Miguel|||0000-0001-6763-0355
  • Garcés Crespo, Miguel|||0000-0001-7666-6392
  • Roca, Eduard|||0000-0002-0827-4175
  • Costa, Elisenda|||0000-0001-7917-0691
  • Ferrer, Oriol|||0000-0001-5545-9992
  • Cabrera, Lluís|||0000-0003-0995-310X
The precise determination of the tectonic deformation timing such as thrust emplacement has always been a challenge for understanding the evolution of fold-and-thrust belts. In the Catalan Coastal Ranges, this issue has traditionally been addressed through the mapping and the analysis of the syn-tectonic successions preserved in the SE margin of the Ebro Basin. However, the age of the Paleogene contractional structures located towards the hinterland and responsible of the inversion and uplift of the inherited Mesozoic structure remained uncertain due to the lack of preserved syn-kinematic strata in these areas. With the aim of better understand the contractional evolution of the area during the Paleogene, this work presents a tectono-stratigraphic analysis approach that combines structural reconstructions, provenance analysis and magnetostratigraphic dating in well-exposed synorogenic sediments in the central SE margin of the Ebro Basin. The results of the study allow to establish the precise age of the main contractional structures present in the central Catalan Coastal Ranges. The combined analysis has revealed that: 1) the inversion of the Montmell-Vallès Faults System started in the Bartonian and continued up to the late Priabonian, and 2) the emplacement of the Gaià-El Camp Thrust and the formation of the Cabra-Carme Anticline took place from early to late Priabonian and was the responsible of the sudden increased of the sedimentation rates. A later decrease of the sedimentation rates during late Priabonian (chron C15n) has been interpreted as the prelude of the end of the Paleogene compressional phase in the area.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting protein-protein interactions in drug discovery, Modulators approved or in clinical trials for cancer treatment

  • Camps-Fajol, Cristina
  • Cavero, Debora|||0000-0002-8912-1890
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Surralles, Jordi|||0000-0002-4041-7519
Protein-protein interactions (PPIs) form complex cellular networks fundamental to many key biological processes, including signal transduction, cell proliferation and DNA repair. In consequence, their perturbation is often associated with many human diseases. Targeting PPIs offers a promising approach in drug discovery and ongoing advancements in this field hold the potential to provide highly specific therapies for a wide range of complex diseases. Despite the development of PPI modulators is challenging, advances in the genetic, proteomic and computational level have facilitated their discovery and optimization. Focusing on anticancer drugs, in the last years several PPI modulators have entered clinical trials and venetoclax, which targets Bcl-2 family proteins, has been approved for treating different types of leukemia. This review discusses the clinical development status of drugs modulating several PPIs, such as MDM2-4/p53, Hsp90/Hsp90, Hsp90/CDC37, c-Myc/Max, KRAS/SOS1, CCR5/CCL5, CCR2/CCL2 or Smac/XIAP, in cancer drug discovery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

New workflow for bridging the gap between geology knowledge and society, the example of the VIGEOCULT Project and the Orígens Geopark South-Central Pyrenees

  • Carola Molas, Eloi|||0000-0003-2528-150X
  • Muñoz, Josep Anton|||0000-0003-0740-879X
  • Santolaria, Pablo|||0000-0002-2408-809X
  • Gratacós Torrà, Òscar|||0000-0002-5328-9114
  • Ferrer, Oriol|||0000-0001-5545-9992
  • De Matteis, Marco|||0000-0002-0198-692X
  • Rivas Casamajó, Gonzalo
  • Galobart, Àngel|||0000-0003-1508-4561
  • Sellés, Albert|||0000-0002-4637-6084
  • Dinarès Cabrerizo, Oriol|||0000-0002-8494-5524
  • Mir, Xavier
  • Puras, Guillem|||0009-0003-4786-3452
  • Yagüe Medina, Aroa|||0009-0009-8144-7990
  • Vallès, Jan
  • Muñiz olivares, José Antonio
The effective dissemination of geological content in an engaging and easy-to-follow manner is challenging, especially because in most situations the general public has a limited geological background. This is particularly evident when considering dissemination outdoors. This study introduces a comprehensive workflow and methodology designed to transform complex geological research into accessible and engaging content for visitors to the Orígens UNESCO Global Geopark - hereinafter simply referred to as Orígens Geopark - in the southern Pyrenees. This workflow brings accurate geological research together with leading-edge graphical design techniques to create a set of outreach products such as virtual reality images, 3D models and 4D reconstructions of the past geological landscapes. Despite the potential of the workflow to create leading-edge dissemination products, some limitations have also been identified and are discussed here. This workflow developed for the project entitled "A natural open museum in the Pyrenees: virtual reality experience for dissemination and conservation of the geological and cultural heritage (VIGEOCULT) is applicable not only to Orígens Geopark but also in the tourism sector, educational (from elementary to university level) outreach in villages and schools, and public dissemination events.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma

  • Anguera, Georgia|||0000-0002-6060-1110
  • Gallego Rubio, Oscar|||0000-0001-5665-0967
  • Llobet, Mireia
  • Berga, Núria|||0009-0002-1488-8998
  • Moreno Martinez, Maria Estela|||0000-0001-6752-873X
  • Leon, Xavier
  • Kratz, Christian
  • Garcia-Escudero, Ramon|||0000-0001-5640-6542
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Surralles, Jordi|||0000-0002-4041-7519
Individuals diagnosed with Fanconi anemia (FA) present an incidence of 500- to 700-fold higher to develop head and neck squamous carcinomas (HNSCCs) compared to the general population. Effective anticancer treatments for FA-HNSCCs are missing. Several studies demonstrated that FA-HNSCCs overexpress the epithelial growth factor receptor (EGFR) and their viability is highly dependent on this pathway, as FA-HNSCCs cells are highly sensitive to EGFR inhibitors such as afatinib in preclinical models, which led to an orphan drug designation by EMA in 2018. The AFAN trial is a phase Ib/II, single arm, non-randomized, open-label, multicenter study to determine whether afatinib is effective and safe in patients with FA and advanced / metastatic HNSCC. Patients could be treatment-naïve or progressed to a previous systemic treatment with immunotherapy, chemotherapy or cetuximab. Afatinib will be administered orally at a starting dose of 20 mg /day (weeks 1-2), escalating to 30 mg / day at weeks 3-4 and to 40 mg / day thereafter provided no adverse events occur. Treatment will be maintained until disease progression / secondary primary tumor, loss to follow-up, unacceptable toxicity, patient withdrawal or death. Dose reductions and delays will be allowed. All patients will undergo periodic tumor assessments by CT or MRI scan every 12 weeks (3 months) from the start of the study treatment until progression / SPT or patient withdrawal. The primary endpoint is objective response rate (ORR) after 9 months of study treatment initiation according to RECIST V1.1. Secondary endpoints include disease control rate, duration of response, disease-free survival, overall survival, safety, patient reported outcomes and ancillary studies. The expected sample size is 25 patients calculated using a Simon II stage design (α = 0.1; β = 80%), taking as null hypothesis a 9-month ORR of 20% and an alternative ORR of 40%. The AFAN trial will investigate if afatinib is an effective treatment in FA patients with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx.
Repisalud
Publicación Artículo científico (JournalArticle)

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry

  • Marrugal, Ángela
  • Ferrer, Irene
  • Pastor, Maria Dolores
  • Ojeda, Laura
  • Quintanal-Villalonga, Alvaro
  • Carnero, Amancio
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
Heat shock protein 90 (HSP90) is an important chaperone in lung adenocarcinoma, with relevant protein drivers such as EGFR (epidermal growth factor receptor) and EML4-ALK (echinoderm microtubule-associated protein-like protein4 fused to anaplastic lymphoma kinase) depending on it for their correct function, therefore HSP90 inhibitors show promise as potential treatments for lung adenocarcinoma. To study responses to its inhibition, HSP90 was pharmacologically interrupted by geldanamycin and resorcinol derivatives or with combined inhibition of HSP90 plus HSP70 in lung adenocarcinoma cell lines. Two-dimensional electrophoresis was performed to identify proteomic profiles associated with inhibition which will help to understand the biological basis for the responses. HSP90 inhibition resulted in altered protein profiles that differed according the treatment condition studied. Results revealed 254 differentially expressed proteins after treatments, among which, eukaryotic translation initiation factor3 subunit I (eIF3i) and citrate synthase demonstrated their potential role as response biomarkers. The differentially expressed proteins also enabled signalling pathways involved in responses to be identified; these included apoptosis, serine-glycine biosynthesis and tricarboxylic acid cycle. The proteomic profiles identified here contribute to an improved understanding of HSP90 inhibition and open possibilities for the detection of potential response biomarkers which will be essential to maximize treatment efficacy in lung adenocarcinoma.
Repisalud
Publicación Artículo científico (JournalArticle)

Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer

  • Quintanal-Villalonga, Alvaro
  • Mediano, Mariló
  • Ferrer, Irene
  • Meléndez, Ricardo
  • Carranza-Carranza, Andrés
  • Suárez, Rocío
  • Carnero, Amancio
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
Lung tumors represent a major health problem. In early stage NSCLC tumors, surgical resection is the preferred treatment, but 30-55% of patients will relapse within 5 years after surgery. Thus, the identification of prognostic biomarkers in early stage NSCLC patients, especially those which are therapeutically addressable, is crucial to enhance survival of these patients. We determined the immunohistochemistry expression of key proteins involved in tumorigenesis and oncogenic signaling, p53, EGFR, pAKT and pERK, and correlated their expression level to clinicopathological characteristics and patient outcome. We found EGFR expression is higher in the squamous cell carcinomas than in adenocarcinomas (p=0.043), and that nuclear p53 staining correlated with lower differentiated squamous tumors (p=0.034). Regarding the prognostic potential of the expression of these proteins, high pERK levels proved to be an independent prognostic factor for overall (p<0.001) and progression-free survival (p<0.001) in adenocarcinoma patients, but not in those from the squamous histology, and high p53 nuclear levels were identified as independent prognostic factor for progression-free survival (p=0.031) only in squamous cell carcinoma patients. We propose a role as early prognostic biomarkers for pERK protein levels in adenocarcinoma, and for nuclear p53 levels in squamous cell lung carcinoma. The determination of these potential biomarkers in the adequate histologic context may predict the outcome of early stage NSCLC patients, and may offer a therapeutic opportunity to enhance survival of these patients.
Repisalud
Publicación Artículo científico (JournalArticle)

Delineating distinct heme-scavenging and -binding functions of domains in MF6p/helminth defense molecule (HDM) proteins from parasitic flatworms

  • Martínez-Sernández, Victoria
  • Mezo, Mercedes
  • González-Warleta, Marta
  • Perteguer-Prieto, Maria Jesus
  • Garate, Teresa
  • Romarís, Fernanda
  • Ubeira, Florencio M
MF6p/FhHDM-1 is a small protein secreted by the parasitic flatworm (trematode) Fasciola hepatica that belongs to a broad family of heme-binding proteins (MF6p/helminth defense molecules (HDMs)). MF6p/HDMs are of interest for understanding heme homeostasis in trematodes and as potential targets for the development of new flukicides. Moreover, interest in these molecules has also increased because of their immunomodulatory properties. Here we have extended our previous findings on the mechanism of MF6p/HDM-heme interactions and mapped the protein regions required for heme binding and for other biological functions. Our data revealed that MF6p/FhHDM-1 forms high-molecular-weight complexes when associated with heme and that these complexes are reorganized by a stacking procedure to form fibril-like and granular nanostructures. Furthermore, we showed that MF6p/FhHDM-1 is a transitory heme-binding protein as protein·heme complexes can be disrupted by contact with an apoprotein (e.g. apomyoglobin) with higher affinity for heme. We also demonstrated that (i) the heme-binding region is located in the MF6p/FhHDM-1 C-terminal moiety, which also inhibits the peroxidase-like activity of heme, and (ii) MF6p/HDMs from other trematodes, such as Opisthorchis viverrini and Paragonimus westermani, also bind heme. Finally, we observed that the N-terminal, but not the C-terminal, moiety of MF6p/HDMs has a predicted structural analogy with cell-penetrating peptides and that both the entire protein and the peptide corresponding to the N-terminal moiety of MF6p/FhHDM-1 interact in vitro with cell membranes in hemin-preconditioned erythrocytes. Our findings suggest that MF6p/HDMs can transport heme in trematodes and thereby shield the parasite from the harmful effects of heme.
Repisalud
Publicación Artículo científico (JournalArticle)

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

  • Ferrer, Irene
  • Quintanal-Villalonga, Alvaro
  • Molina-Pinelo, Sonia
  • Garcia-Heredia, Jose Manuel
  • Perez, Marco
  • Suárez, Rocío
  • Ponce-Aix, Santiago
  • Paz Ares , Luis Gonzaga
  • Carnero, Amancio
BACKGROUND: The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient survival. MAP17 (PDZK1IP1) is a small membrane-bound protein whose upregulation is reported as a common feature in tumours from diverse histological origins. Furthermore, MAP17 is correlated with tumour progression. METHODS: We assessed the expression of MAP17 in preclinical models, including cell lines and patient-derived xenografts (PDXs), assessing its correlation with sensitivity to different standard-of-care drugs in lung adenocarcinoma, as well as novel drugs. At the clinical level, we subsequently correlated MAP17 expression in human tumours with patient response to these therapies. RESULTS: We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors. In addition, we show that MAP17 expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas. CONCLUSIONS: Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy. Furthermore, we propose bortezomib treatment as a novel and efficacious therapy for lung adenocarcinomas exhibiting high MAP17 expression.
Repisalud
Publicación Artículo científico (JournalArticle)

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction

  • Quintanal-Villalonga, Alvaro
  • Ojeda-Marquez, Laura
  • Marrugal, Ángela
  • Yagüe, Patricia
  • Ponce-Aix, Santiago
  • Salinas, Ana
  • Carnero, Amancio
  • Ferrer, Irene
  • Molina-Pinelo, Sonia
  • Paz Ares , Luis Gonzaga
The FGFR4-388Arg variant has been related to poor prognosis in several types of cancer, including lung cancer. The mechanism underlying this association has not been addressed in detail in patients with this pathology. Here, we report that this FGFR4 variant induces MAPK and STAT3 activation and causes pro-oncogenic effects in NSCLC in vitro and in vivo. This variant induces the expression of EMT-related genes, such as N-cadherin, vimentin, Snail1 and Twist1. Indeed, the induction of N-cadherin protein expression by this variant is essential for its pro-tumorigenic role. The presence of the FGFR4-388Arg variant correlates with higher N-cadherin expression levels in clinical NSCLC samples and with poorer outcome in patients with FGFR expression. These results support the prognostic role of this FGFR variant in lung cancer and show that these effects may be mediated by the induction of N-cadherin expression and an EMT phenotype.
Repisalud
Publicación Artículo científico (JournalArticle)

Transferable AmpCs in Klebsiella pneumoniae: interplay with peptidoglycan recycling, mechanisms of hyperproduction, and virulence implications

  • Barceló, Isabel M
  • Escobar-Salom, Maria
  • Cabot, Gabriel
  • Perelló-Bauzà, Pau
  • Jordana-Lluch, Elena
  • Taltavull, Biel
  • Torrens, Gabriel
  • Rojo-Molinero, Estrella
  • Zamorano, Laura
  • Perez Gomez, Astrid
  • Oliver, Antonio
  • Juan, Carlos
Chromosomal and transferable AmpC β-lactamases represent top resistance mechanisms in different gram-negatives, but knowledge regarding the latter, mostly concerning regulation and virulence-related implications, is far from being complete. To fill this gap, we used Klebsiella pneumoniae (KP) and two different plasmid-encoded AmpCs [DHA-1 (AmpR regulator linked, inducible) and CMY-2 (constitutive)] as models to perform a study in which we show that blockade of peptidoglycan recycling through AmpG permease inactivation abolished DHA-1 inducibility but did not affect CMY-2 production and neither did it alter KP pathogenic behavior. Moreover, whereas regular production of both AmpC-type enzymes did not attenuate KP virulence, when blaDHA-1 was expressed in an ampG-defective mutant, Galleria mellonella killing was significantly (but not drastically) attenuated. Spontaneous DHA-1 hyperproducer mutants were readily obtained in vitro, showing slight or insignificant virulence attenuations together with high-level resistance to β-lactams only mildly affected by basal production (e.g., ceftazidime, ceftolozane/tazobactam). By analyzing diverse DHA-1-harboring clinical KP strains, we demonstrate that the natural selection of these hyperproducers is not exceptional (>10% of the collection), whereas mutational inactivation of the typical AmpC hyperproduction-related gene mpl was the most frequent underlying mechanism. The potential silent dissemination of this kind of strains, for which an important fitness cost-related contention barrier does not seem to exist, is envisaged as a neglected threat for most β-lactams effectiveness, including recently introduced combinations. Analyzing whether this phenomenon is applicable to other transferable β-lactamases and species as well as determining the levels of conferred resistance poses an essential topic to be addressed. IMPORTANCE: Although there is solid knowledge about the regulation of transferable and especially chromosomal AmpC β-lactamases in Enterobacterales, there are still gaps to fill, mainly related to regulatory mechanisms and virulence interplays of the former. This work addresses them using Klebsiella pneumoniae as model, delving into a barely explored conception: the acquisition of a plasmid-encoded inducible AmpC-type enzyme whose production can be increased through selection of chromosomal mutations, entailing dramatically increased resistance compared to basal expression but minor associated virulence costs. Accordingly, we demonstrate that clinical K. pneumoniae DHA-1 hyperproducer strains are not exceptional. Through this study, we warn for the first time that this phenomenon may be a neglected new threat for β-lactams effectiveness (including some recently introduced ones) silently spreading in the clinical context, not only in K. pneumoniae but potentially also in other pathogens. These facts must be carefully considered in order to design future resistance-preventive strategies.
Repisalud
Publicación Artículo científico (JournalArticle)

Cytosolic protein translation regulates cell asymmetry and function in early TCR activation of human CD8 T lymphocytes.

  • Gómez-Morón, Álvaro
  • Tsukalov, Ilya
  • Scagnetti, Camila
  • Pertusa, Clara
  • Lozano-Prieto, Marta
  • Martínez-Fleta, Pedro
  • Requena, Silvia
  • Martín, Pilar
  • Alfranca, Aranzazu
  • Martin-Gayo, Enrique
  • Martin-Cofreces, Noa B
CD8 cytotoxic T lymphocytes (CTLs) are highly effective in defending against viral infections and tumours. They are activated through the recognition of peptide-MHC-I complex by the T-cell receptor (TCR) and co-stimulation. This cognate interaction promotes the organisation of intimate cell-cell connections that involve cytoskeleton rearrangement to enable effector function and clearance of the target cell. This is key for the asymmetric transport and mobilisation of lytic granules to the cell-cell contact, promoting directed secretion of lytic mediators such as granzymes and perforin. Mitochondria play a role in regulating CTL function by controlling processes such as calcium flux, providing the necessary energy through oxidative phosphorylation, and its own protein translation on 70S ribosomes. However, the effect of acute inhibition of cytosolic translation in the rapid response after TCR has not been studied in mature CTLs. Here, we investigated the importance of cytosolic protein synthesis in human CTLs after early TCR activation and CD28 co-stimulation for the dynamic reorganisation of the cytoskeleton, mitochondria, and lytic granules through short-term chemical inhibition of 80S ribosomes by cycloheximide and 80S and 70S by puromycin. We observed that eukaryotic ribosome function is required to allow proper asymmetric reorganisation of the tubulin cytoskeleton and mitochondria and mTOR pathway activation early upon TCR activation in human primary CTLs. Cytosolic protein translation is required to increase glucose metabolism and degranulation capacity upon TCR activation and thus to regulate the full effector function of human CTLs.
Repisalud
Publicación Artículo científico (JournalArticle)

Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement

  • Quintanal-Villalonga, Alvaro
  • Carranza-Carranza, Andrés
  • Meléndez, Ricardo
  • Ferrer, Irene
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
BACKGROUND: The identification of prognostic biomarkers for lung squamous-cell carcinoma (SCC) pathology is crucial because of its poor prognosis. A variant of the FGFR4 (fibroblast growth factor receptor 4) gene, FGFR4-388Arg, has been associated with prognosis and is linked to oncogenesis in vitro in several types of cancer. We analyzed the association of this variant with prognosis and downstream signaling alteration in lung SCC patients. METHODS: The presence of the FGFR4-388Arg variant was determined in 114 formalin-fixed, paraffin-embedded lung SCC tissue samples by DNA genotyping and was correlated with clinicopathologic data. The activation of the protein kinase B (AKT) and mitogen-activated protein kinase (MAPK) pathways was determined by immunohistochemistry, and its association with the presence of FGFR4-388Arg was analyzed. RESULTS: We found that tumor differentiation status and adjuvant chemotherapy administration could be independent prognostic factors for overall survival (OS) in lymph node-affected patients, as expected. The progression-free survival and OS of patients with lymph node involvement (n = 41) and the FGFR4-388Arg genotype were significantly lower than those of patients lacking this variant (P = .035 and P = .042, respectively). Importantly, multivariate analysis supported the independent prognostic role of the FGFR4-388Arg genotype in OS (P = .025). Regarding downstream signaling, the FGFR4-388Arg genotype was not correlated with altered AKT signaling but was associated with increased MAPK activation in the SCC tumor samples (P = .017). CONCLUSION: The FGFR4-388Arg variant may represent a promising prognostic biomarker in SCC patients with lymph node involvement. For these patients, FGFR4 may be a potential therapeutic target.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer

  • Loras, Alba
  • Suárez-Cabrera, Cristian
  • Quintás, Guillermo
  • Paramio, Jesús M.
  • Gil Grau, Salvador
  • Ruiz-Cerdá, José Luis
  • Martínez-Bisbal, M.Carmen|||0000-0002-8526-4413
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Metabolism reprogramming is considered a hallmark of cancer. The study of bladder cancer (BC) metabolism could be the key to developing new strategies for diagnosis and therapy. This work aimed to identify tissue and urinary metabolic signatures as biomarkers of BC and get further insight into BC tumor biology through the study of gene-metabolite networks and the integration of metabolomics and transcriptomics data. BC and control tissue samples (n = 44) from the same patients were analyzed by High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance and microarrays techniques. Besides, urinary profiling study (n = 35) was performed in the same patients to identify a metabolomic profile, linked with BC tissue hallmarks, as a potential non-invasive approach for BC diagnosis. The metabolic profile allowed for the classification of BC tissue samples with a sensitivity and specificity of 100%. The most discriminant metabolites for BC tissue samples reflected alterations in amino acids, glutathione, and taurine metabolic pathways. Transcriptomic data supported metabolomic results and revealed a predominant downregulation of metabolic genes belonging to phosphorylative oxidation, tricarboxylic acid cycle, and amino acid metabolism. The urinary profiling study showed a relation with taurine and other amino acids perturbed pathways observed in BC tissue samples, and classified BC from non-tumor urine samples with good sensitivities (91%) and specificities (77%). This urinary profile could be used as a non-invasive tool for BC diagnosis and follow-up., This research was funded by FEDER cofounded MINECO grant SAF2015-66015-R, MAT2015-64139-C4-1-R, MAT2015-64139-C4-3-R, ISCIII-RETICRD12/0036/0009, PIE 15/00076, CB/16/00228, CTQ2016-79561-P; and the PROMETEO II/2014/047 and PROMETEO 2018/24 projects.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Effect of sintering temperature on cation distribution in CoFe2O4 nanoparticles

  • Bilovol, V
  • Jelén, P
  • Mech, K
  • Sokolowski, K
  • Botella, P.
  • Errandonea, Daniel
  • Bandiello, Enrico|||0000-0003-0956-3195
  • Manjón, Francisco-Javier|||0000-0002-3926-1705
[EN] We report a study of the cation arrangement in CoFe2O4 nanoparticles synthesized using a co-precipitation method followed by high-temperature sintering in the range of 500-1000 degrees C. Analysis of the samples by Raman, infrared, and X-ray photoelectron spectroscopy (Fe 2p3/2 and Co 2p3/2) revealed that the sintering temperature influences the distribution of cations in the spinel lattice. Specifically, increasing the sintering temperature leads to an increase in the inversion degree parameter (gamma), which represents the fraction of Co ions residing in octahedral sites, driving the structure toward a fully inverted spinel. These results are in good agreement with those previously obtained by 57Fe Mo<spacing diaeresis>ssbauer spectroscopy, X-ray diffraction, and X-ray absorption experiments on the same set of samples. Additionally, as shown by the UV-visible spectra, the cationic distribution in the samples clearly affects the band gap value (2.5-2.8 eV)., This research was partly supported by the program "Excellence Initiative-Research University" for the AGH University of Krakow. This publication is financed by the Spanish Ministerio de Ciencia, Innovacion Universidades (MCIU) and the Agencia Estatal de Investigacion (AEI) (https://doi.org/10.13039/501100011033) as part of the project MALTA Consolider Team network (RED2022-134388-T) , and I + D + i projects PID2022-138076NB-C41/C42 co-financed by EU FEDER funds. This publication is also financed by Generalitat Valenciana through grants PROMETEO CIPROM/2021/075-GREENMAT, MFA/2022/007, and MFA/2022/025 (ARCANGEL) . This study forms part of the Advanced Materials program and is supported by MCIN with funding from the European Union Next Generation EU (PRTR-C17.I1) and by the Generalitat Valenciana. We thank Dr. M. Marzec and. Dr. D. Lachowicz for their help with the XPS and optical measurements, respectively. V.B. is thankful to the Polish National Agency for Academic Exchange (NAWA) for the fellowship (BPN/ULM/2021/1/00076) .
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants

  • Fraile-Ribot, Pablo Arturo
  • Zamorano, Laura
  • Orellana, Rocío
  • del Barrio-Tofiño, Ester
  • Sánchez-Diener, Irina
  • Cortés-Lara, Sara
  • López-Causapé, Carla
  • Cabot, Gabriel
  • Bou, Germán
  • Martínez-Martínez, Luis
  • Oliver, Antonio
[Abstract] Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC., The work was supported by MSD and by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), and grant PI18/00076 cofinanced by European Regional Development Fund (ERDF) “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. The work was partially financed by MSD through Investigator Initiated Studies Program to A.O.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Rodiño-Janeiro, Bruno Kotska
  • Cabot, Gabriel
  • Vázquez-Ucha, Juan Carlos
  • Rodríguez-Iglesias, Manuel
  • Galán-Sánchez, Fátima
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: The development of resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of Pseudomonas aeruginosa infections is concerning. Objectives: Characterization of the mechanisms leading to the development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR P. aeruginosa infections. Methods: Four paired ceftolozane/tazobactam- and ceftazidime/avibactam-susceptible/resistant isolates were evaluated. MICs were determined by broth microdilution. STs, resistance mechanisms and genetic context of β-lactamases were determined by genotypic methods, including WGS. The OXA-10 variants were cloned in PAO1 to assess their impact on resistance. Models for the OXA-10 derivatives were constructed to evaluate the structural impact of the amino acid changes. Results: The same XDR ST253 P. aeruginosa clone was detected in all four cases evaluated. All initial isolates showed OprD deficiency, produced an OXA-10 enzyme and were susceptible to ceftazidime, ceftolozane/tazobactam, ceftazidime/avibactam and colistin. During treatment, the isolates developed resistance to all cephalosporins. Comparative genomic analysis revealed that the evolved resistant isolates had acquired mutations in the OXA-10 enzyme: OXA-14 (Gly157Asp), OXA-794 (Trp154Cys), OXA-795 (ΔPhe153-Trp154) and OXA-824 (Asn143Lys). PAO1 transformants producing the evolved OXA-10 derivatives showed enhanced ceftolozane/tazobactam and ceftazidime/avibactam resistance but decreased meropenem MICs in a PAO1 background. Imipenem/relebactam retained activity against all strains. Homology models revealed important changes in regions adjacent to the active site of the OXA-10 enzyme. The blaOXA-10 gene was plasmid borne and acquired due to transposition of Tn6746 in the pHUPM plasmid scaffold. Conclusions: Modification of OXA-10 is a mechanism involved in the in vivo acquisition of resistance to cephalosporin/β-lactamase inhibitor combinations in P. aeruginosa., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support and relebactam. This work was also supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III (ISCIII), through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O. and P14/00059 and P17/01482 to A.B. Support was also provided by: Planes Nacionales de I + D+i 2013-2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth Program 2014-2020. C.G.-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)] and the European Regional Development Fund (ERDF). J.A.-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-Especialización Grant (2019) and by the Rio Hortega Program (ISCIII, CM19/00219). J.C.V.-U. was financially supported by the pFIS Program (ISCIII, PI17/01482). C.L.-M. was financially supported by an IN606A-2019/029 Grant (Xunta de Galicia).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

  • Arca-Suárez, Jorge
  • Vázquez-Ucha, Juan Carlos
  • Fraile-Ribot, Pablo Arturo
  • Lence, Emilio
  • Cabot, Gabriel
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Rodríguez-Iglesias, Manuel
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Galán-Sánchez, Fátima
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: Pseudomonas aeruginosa may develop resistance to novel cephalosporin/β-lactamase inhibitor combinations during therapy through the acquisition of structural mutations in AmpC. Objectives: To describe the molecular and biochemical mechanisms involved in the development of resistance to ceftolozane/tazobactam in vivo through the selection and overproduction of a novel AmpC variant, designated PDC-315. Methods: Paired susceptible/resistant isolates obtained before and during ceftolozane/tazobactam treatment were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. Characterization of the novel PDC-315 variant was performed through genotypic and biochemical studies. The effects at the molecular level of the Asp245Asn change were analysed by molecular dynamics simulations using Amber. Results: WGS identified mutations leading to modification (Asp245Asn) and overproduction of AmpC. Susceptibility testing revealed that PAOΔC producing PDC-315 displayed increased MICs of ceftolozane/tazobactam, decreased MICs of piperacillin/tazobactam and imipenem and similar susceptibility to ceftazidime/avibactam compared with WT PDCs. The catalytic efficiency of PDC-315 for ceftolozane was 10-fold higher in relation to the WT PDCs, but 3.5- and 5-fold lower for piperacillin and imipenem. IC50 values indicated strong inhibition of PDC-315 by avibactam, but resistance to cloxacillin inhibition. Analysis at the atomic level explained that the particular behaviour of PDC-315 is linked to conformational changes in the H10 helix that favour the approximation of key catalytic residues to the active site. Conclusions: We deciphered the precise mechanisms that led to the in vivo emergence of resistance to ceftolozane/tazobactam in P. aeruginosa through the selection of the novel PDC-315 enzyme. The characterization of this new variant expands our knowledge about AmpC-mediated resistance to cephalosporin/β-lactamase inhibitors in P. aeruginosa., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O., and P14/00059 and P17/01482 to A.B. Support was also provided by Planes Nacionales de I + D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth program 2014–2020. C.G-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R, C.G-B.), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)], and the European Regional Development Fund (ERDF). E.L. thanks the Xunta de Galicia for his postdoctoral fellowship. J.A-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-especialización Grant (2019) and by the Rio Hortega program (ISCIII, CM19/00219). J.C.V-U. was financially supported by the pFIS program (ISCIII, PI17/01482). M.M-G. was financially supported by a Clara Roy grant (SEIMC) and C.L-M. by IN606A-2019/029.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology

  • del Barrio-Tofiño, Ester
  • Zamorano, Laura
  • Cortés-Lara, Sara
  • López-Causapé, Carla
  • Sánchez-Diener, Irina
  • Cabot, Gabriel
  • Bou, Germán
  • Martínez-Martínez, Luis
  • Oliver, Antonio
[Abstract] Objectives: To undertake a Spanish nationwide survey on Pseudomonas aeruginosa molecular epidemiology and antimicrobial resistance. Methods: Up to 30 consecutive healthcare-associated P. aeruginosa isolates collected in 2017 from each of 51 hospitals were studied. MICs of 13 antipseudomonal agents were determined by broth microdilution. Horizontally acquired β-lactamases were detected by phenotypic methods and PCR. Clonal epidemiology was evaluated through PFGE and MLST; at least one XDR isolate from each clone and hospital (n = 185) was sequenced. Results: The most active antipseudomonals against the 1445 isolates studied were colistin and ceftolozane/tazobactam (both 94.6% susceptible, MIC50/90 = 1/2 mg/L) followed by ceftazidime/avibactam (94.2% susceptible, MIC50/90 = 2/8 mg/L). Up to 252 (17.3%) of the isolates were XDR. Carbapenemases/ESBLs were detected in 3.1% of the isolates, including VIM, IMP, GES, PER and OXA enzymes. The most frequent clone among the XDR isolates was ST175 (40.9%), followed by CC235 (10.7%), ST308 (5.2%) and CC111 (4.0%). Carbapenemase production varied geographically and involved diverse clones, including 16.5% of ST175 XDR isolates. Additionally, 56% of the sequenced XDR isolates showed horizontally acquired aminoglycoside-modifying enzymes, which correlated with tobramycin resistance. Two XDR isolates produced QnrVC1, but fluoroquinolone resistance was mostly caused by QRDR mutations. Beyond frequent mutations (>60%) in OprD and AmpC regulators, four isolates showed AmpC mutations associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam. Conclusions: ST175 is the most frequent XDR high-risk clone in Spanish hospitals, but this nationwide survey also indicates a complex scenario in which major differences in local epidemiology, including carbapenemase production, need to be acknowledged in order to guide antimicrobial therapy., This work was supported by MSD (through a grant to A. O.) and by Plan Nacional de I + D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016) and grants PI15/00088 and PI18/00076 co-financed by European Regional Development Fund ERDF ‘A way to achieve Europe’, Operative program Intelligent Growth 2014–2020. The funders had no role in the design, execution, analysis or reporting of the research.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study

  • Lasarte-Monterrubio, Cristina
  • Guijarro, Paula
  • Alonso-García, Isaac
  • Outeda-García, Michelle
  • Maceiras, Romina
  • González-Pinto, Lucía
  • Martínez Guitián, Marta
  • Fernández-Lozano, Carlos
  • Vázquez-Ucha, Juan Carlos
  • Bou, Germán
  • Arca-Suárez, Jorge
  • Beceiro Casas, Alejandro
[Abstract]: Background: As increasing antibiotic resistance in Acinetobacter baumannii poses a global healthcare challenge, understanding its evolution is crucial for effective control strategies. Aim: We aimed to evaluate the epidemiology, antimicrobial susceptibility and main resistance mechanisms of Acinetobacter spp. in Spain in 2020, and to explore temporal trends of A. baumannii. Methods: We collected 199 single-patient Acinetobacter spp. clinical isolates in 2020 from 18 Spanish tertiary hospitals. Minimum inhibitory concentrations (MICs) for nine antimicrobials were determined. Short-read sequencing was performed for all isolates, and targeted long-read sequencing for A. baumannii. Resistance mechanisms, phylogenetics and clonality were assessed. Findings on resistance rates and infection types were compared with data from 2000 and 2010. Results: Cefiderocol and colistin exhibited the highest activity against A. baumannii, although colistin susceptibility has significantly declined over 2 decades. A. non-baumannii strains were highly susceptible to most tested antibiotics. Of the A. baumannii isolates, 47.5% (56/118) were multidrug-resistant (MDR). Phylogeny and clonal relationship analysis of A. baumannii revealed five prevalent international clones, notably IC2 (ST2, n = 52; ST745, n = 4) and IC1 (ST1, n = 14), and some episodes of clonal dissemination. Genes blaOXA-23, blaOXA-58 and blaOXA-24/40 were identified in 49 (41.5%), eight (6.8%) and one (0.8%) A. baumannii isolates, respectively. ISAba1 was found upstream of the gene (a blaOXA-51-like) in 10 isolates. Conclusions: The emergence of OXA-23-producing ST1 and ST2, the predominant MDR lineages, shows a pivotal shift in carbapenem-resistant A. baumannii (CRAB) epidemiology in Spain. Coupled with increased colistin resistance, these changes underscore notable alterations in regional antimicrobial resistance dynamics., This work was supported by Projects PI20/01212 and PI23/00851 awarded to AB, Project PI21/00704 awarded to GB, and Project PI22/01212 awarded to JA-S, funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. The work was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- de Enfermedades Infecciosas, Instituto de Salud Carlos III (CB21/13/00055), Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU and by project IN607A 2020/05 (GAIN-Agencia Gallega de InnovaciónConsellería de Economía, Emprego e Industria) awarded to GB and project IN607D 2021/12 awarded to AB. JA-S was financially supported by the Juan Rodés program (ISCIII, JR21/00026), JCV-U was financially supported by IN606B-2022/009 (Xunta de Galicia), CL-M was financially supported by PI20/01212 (ISCIII), PG-S was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). MO was financially supported by IN607D 2021/12. IA-G was financially supported by the Rio Hortega program (ISCIII, CM21/00076). MM-G was financially supported by RSU.UDC.M505 (Ministerio de Universidades)., Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; IN607D 2021/12, Universidade da Coruña; RSU.UDC.M505
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Drivers of extended-spectrum β-lactamase (ESBL)- producing Enterobacterales colonization among residents of long-term care facilities: a European multicentre prospective cohort study

  • Göpel, Siri
  • Guther, Julia
  • Gladstone, Beryl Primrose
  • Conzelmann, Nadine
  • Bunk, Stefanie
  • Terzer, Tobias
  • Verschuuren, T. D.
  • Martak, Daniel
  • Salamanca, Elena
  • Autenrieth, I. B.
  • Peter, Silke
  • Kluytmans, Jan
  • Hocquet, Didier
  • Rodríguez-Baño, Jesús
  • Tacconelli, Evelina
The preliminary results of this study were presented online at the 30th European Congress of Clinical Microbiology and Infectious Diseases in Paris, France in April 2020 (Abstract # 6724)., MODERN WP1 Study Group (in addition to the authors listed above) Tübingen: Simone Eisenbeis, Florian Hölzl. Seville: Alvaro Pascual, Rocío Medina. Utrecht: Ad Fluit. All the authors stated above meet the required criteria of the International Committee of Medical Journal Editors., Background: Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-PE) are highly prevalent in long-term care (LTCF) settings. In order to estimate the acquisition rate of ESBL-producing Escherichia coli and Klebsiella pneumoniae in LTCF settings, and identify clinical and environmental risk factors, a multi-centre, prospective cohort study was conducted in six LTCFs in Germany, France, Spain and the Netherlands., Methods: Longitudinal screening of residents was performed over 32 weeks, collecting epidemiological and clinical data and environmental samples. The primary outcome was the rate of new acquisition of ESBL-PE among LTCF residents. Molecular epidemiology was studied using whole genome sequencing, and risk factor analysis was undertaken using logistic and Poisson regression models., Results: In total, 299 residents provided 1958 samples during follow-up. The prevalence of ESBL-PE colonization at baseline was 16.4%, and the incidence of acquisition was 0.79 per 1000 resident-days, both with high variability between LTCFs. Age ≥80 years, vascular disease and antibiotic consumption within the preceding year were risk factors for baseline colonization. Lack of hand sanitizers and a low nurse:resident ratio were associated with colonization. The presence of medical devices was associated with risk of acquisition. Vascular disease, hemiplegia, antibiotic consumption, and non-availability of private bathrooms were associated with carriage of multiple sequence types (STs). The prevalence of ESBL-PE among environmental samples was 2%, exclusively in LTCFs with high prevalence among residents. Genetic analysis showed a high prevalence of ST10 E. coli and ST405 K. pneumoniae at two study sites., Conclusion: Infection prevention interventions, including availability of hand sanitizers, the number of nurses per resident, and antimicrobial stewardship, constitute important measures to control ESBL-PE in LTCFs. Genome-based surveillance could guide targeted interventions., This study was part of a Joint Programming Initiative on Antimicrobial Resistance collaborative research project, under the 2016 Joint Call Framework (Transnational Research Projects on the Transmission Dynamics of Antibacterial Resistance). It received funding from the following national research agencies: Spain: Instituto de Salud Carlos III (grant no. AC16/00076), Netherlands: Netherlands Organization for Health Research and Development (grant no. AC681055), France: Agence Nationale de la Recherche (grant no. ANR-16-JPEC-0007-03) and Germany: German Federal Ministry of Education and Research (grant no. 01KI1701). As part of a separate research project, ES, MD-V and JR-B received support for research from the Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001), co- financed by the European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligence Growth 2014-2020. BPG is funded by the German Centre for Infection Research Clinical Research Unit (DZIF-CRU) at Tübingen. The funders played no role in the study design, collection, analysis and interpretation of data, writing and submission for publication., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

  • Puente, J.
  • Laínez, N.
  • Dueñas, M.
  • Méndez-Vidal, M.J.
  • Esteban, E.
  • Castellano, D.
  • Martinez-Fernández, M.
  • Basterretxea, L.
  • Juan-Fita, M.J.
  • Antón, L.
  • León, L.
  • Lambea, J.
  • Pérez-Valderrama, B.
  • Vázquez, S.
  • Suarez, C.
  • del Muro, X.G.
  • Gallardo, E.
  • Maroto, J.P.
  • Luz, Samaniego, M.
  • Suárez-Paniagua, B.
  • Sanz, J.
  • Paramio, J.M.
Background: Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. Patients and methods: Multicenter, observational, retrospective study in patients with clear-cell mRCC treated with sunitinib. Patients were classified in two groups: long-term responders (LR) (progression-free survival (PFS)=22 months and at least stable disease), and primary refractory (PR) (progressive disease within 3-months of sunitinib onset). Objectives were to compare baseline clinical factors in both populations and to correlate tumor expression of selected signaling pathways components with sunitinib PFS. Results: 123 patients were analyzed (97 LR, 26 PR). In the LR cohort, overall response rate was 79% and median duration of best response was 30 months. Median PFS and overall survival were 43.2 (95% confidence intervals[CI]:37.2-49.3) and 63.5 months (95%CI:55.1-71.9), respectively. At baseline PR patients had a significantly lower proportion of nephrectomies, higher lactate dehydrogenase and platelets levels, lower hemoglobin, shorter time to and higher presence of metastases, and increased Fuhrman grade. Higher levels of HEYL, HEY and HES1 were observed in LR, although only HEYL discriminated populations significantly (AUC[ROC]=0.704; cut-off=34.85). Increased levels of hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p were also associated with prolonged survival. No statistical significant associations between hsa-miR-23b or hsa-miR-27b and the expression of c-Met were found. Conclusions: Certain mRCC patients treated with sunitinib achieve extremely long-term responses. Favorable baseline hematology values and longer time to metastasis may predict longer PFS. HEYL, hsa-miR-27b, hsa-miR-23b and hsa-miR- 628-5p could be potentially used as biomarkers of sunitinib response.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey

  • Del Barrio-Tofiño, Ester
  • Sánchez-Diener, Irina
  • Zamorano, Laura
  • Cortes-Lara, Sara
  • López-Causapé, Carla
  • Cabot, Gabriel
  • Bou, Germán
  • Martínez-Martínez, Luis
  • Oliver, Antonio
  • on behalf of the GEMARA-SEIMC/REIPI Pseudomonas study group
  • Castillo-García, Francisco Javier
  • Seral, Cristina
Objectives: To evaluate the correlation of O-antigen serotypes with resistance profiles and high-risk clones in a Spanish nationwide survey. Methods: Up to 30 consecutive healthcare-associated Pseudomonas aeruginosa isolates were collected during October 2017 from each of 51 hospitals (covering all Spanish regions) with a total of 1445 isolates studied. MICs of 13 antipseudomonal agents and MDR/XDR profiles had been previously determined, as well as whole-genome sequences of 185 representative XDR isolates. O-antigen serotypes (O1–O16) were determined by agglutination using serotype-specific antisera (BioRad). The Pseudomonas aeruginosa serotyper (PAst) program was used for in silico serotyping. Results: The most frequent serotypes were O6 (17.8%), O1 (15.4%) and O11 (13.3%). In contrast, the most frequent serotype among XDR isolates (17.3%) was O4 (34.1%), distantly followed by O11 (15.9%). Within serotypes, XDR phenotypes were more frequent for O12 (60.0%) and O4 (57.3%). The most frequent clone among the XDR isolates was ST175 (40.9%), followed by CC235 (10.7%), ST308 (5.2%) and CC111 (3.6%). Up to 81.6%of XDR ST175 isolates typed O4, whereas 18.4% were non-typeable. O4 genotype was detected in all sequenced (n=55) ST175 isolates. On the other hand, CC235 and ST308 were associated with O11, whereas CC111 was linked to serotype O12. Conclusions: O4 serotype is linked to the MDR/XDR profile of widespread ST175 (typically only susceptible to colistin, amikacin and the novel combinations ceftolozane/tazobactam and ceftazidime/avibactam) and therefore, after local validation, its detection in the microbiology laboratory might be useful for guiding semi-empirical antipseudomonal therapies and infection control measures in Spanish hospitals.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

  • Puente, J.|||0000-0002-6910-1331
  • Laínez, Nuria
  • Dueñas, Marta
  • Mendez Vidal, María José|||0000-0002-7460-1859
  • Esteban, Emilio
  • Castellano, Daniel|||0000-0002-9106-0687
  • Martinez-Fernández, Mónica
  • Basterretxea, Laura
  • Juan-Fita, María José
  • Antón Aparicio, Luís
  • Leon-Mateos, Luis
  • Lambea, Julio
  • Pérez Valderrama, Begoña|||0000-0003-0175-1263
  • Vázquez, Sergio|||0000-0002-2203-0791
  • Suárez, Cristina|||0000-0002-0502-5528
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Gallardo Díaz, Enrique|||0000-0002-1375-3488
  • Maroto Rey, Pablo|||0000-0002-0030-0412
  • Samaniego, M. Luz
  • Suárez-Paniagua, Beatriz
  • Sanz, Julián
  • Paramio, Jesús M.|||0000-0001-7520-3177
Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. Multicenter, observational, retrospective study in patients with clear-cell mRCC treated with sunitinib. Patients were classified in two groups: long-term responders (LR) (progression-free survival (PFS)≥22 months and at least stable disease), and primary refractory (PR) (progressive disease within 3-months of sunitinib onset). Objectives were to compare baseline clinical factors in both populations and to correlate tumor expression of selected signaling pathways components with sunitinib PFS. 123 patients were analyzed (97 LR, 26 PR). In the LR cohort, overall response rate was 79% and median duration of best response was 30 months. Median PFS and overall survival were 43.2 (95% confidence intervals[CI]:37.2-49.3) and 63.5 months (95%CI:55.1-71.9), respectively. At baseline PR patients had a significantly lower proportion of nephrectomies, higher lactate dehydrogenase and platelets levels, lower hemoglobin, shorter time to and higher presence of metastases, and increased Fuhrman grade. Higher levels of HEYL, HEY and HES1 were observed in LR, although only HEYL discriminated populations significantly (AUC[ROC]=0.704; cut-off=34.85). Increased levels of hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p were also associated with prolonged survival. No statistical significant associations between hsa-miR-23b or hsa-miR-27b and the expression of c-Met were found. Certain mRCC patients treated with sunitinib achieve extremely long-term responses. Favorable baseline hematology values and longer time to metastasis may predict longer PFS. HEYL, hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p could be potentially used as biomarkers of sunitinib response.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The earliest basketry in southern Europe, Hunter-gatherer and farmer plant-based technology in Cueva de los Murciélagos (Albuñol)

  • Martínez-Sevilla, Francisco|||0000-0002-1385-3585
  • Herrero Otal, Maria|||0000-0002-3846-1238
  • Martín-Seijo, María|||0000-0003-2924-7763
  • Santana-Cabrera, Jonathan|||0000-0002-9615-8560
  • Lozano Rodríguez, José A.|||0000-0003-4598-4472
  • Maicas Ramos, Ruth|||0000-0001-6093-1016
  • Cubas, Miriam|||0000-0002-2386-8473
  • Homs, Anna
  • Martínez Sánchez, Rafael M.|||0000-0002-8947-117X
  • Bertin, Ingrid|||0000-0003-0914-9242
  • Barroso Bermejo, Rosa|||0000-0003-3129-4497
  • Bueno Ramírez, Primitiva|||0000-0001-8958-8928
  • de Balbín Behrmann, Rodrigo|||0000-0002-5868-1107
  • Palomo Pérez, Antoni|||0000-0001-9954-7310
  • Álvarez-Valero, Antonio M.|||0000-0001-9707-0168
  • Peña-Chocarro, Leonor|||0000-0002-7807-8778
  • Murillo-Barroso, Mercedes|||0000-0002-2271-291X
  • Fernández-Domínguez, Eva|||0000-0002-9447-907X
  • Altamirano García, Manuel|||0000-0002-2217-5149
  • Pardo-Martínez, Rubén|||0000-0003-4457-8536
  • Iriarte Cela, Mercedes|||0000-0002-1316-0842
  • Carrasco Rus, Javier L.|||0000-0002-4912-2258
  • Alfaro Giner, Carmen
  • Piqué Huerta, Raquel|||0000-0002-8253-6874
Plant material culture can offer unique insights into the ways of life of prehistoric societies; however, its perishable nature has prevented a thorough understanding of its diverse and complex uses. Sites with exceptional preservation of organic materials provide a unique opportunity for further research. The burial site of Cueva de los Murciélagos in southern Iberia, uncovered during 19th-century mining activities, contained the best-preserved hunter-gatherer basketry in southern Europe, together with other unique organic artifacts associated with the first farming communities, such as sandals and a wooden hammer. We present 14 14C dates for the perishable artifacts (N = 76), situating the assemblage between the Early and Middle Holocene (c. 7500 to 4200 cal BCE). Our integrated analysis includes raw material determination and technological and chrono-cultural contextualization of this unique and important set of materials.